Friends: This has been a pivotal year for Ovarian Cancer Research Alliance (OCRA), defined by powerful forward momentum—from launching the Global Ovarian Cancer Research Consortium to preparing the Community Accelerated Research Exchange for its debut, expanding essential support and education programs, and establishing our new Center for Public Policy. These developments, along with the progress highlighted below, signal a turning point and the urgency of pushing even harder in the year ahead.
Thank you for driving this progress. As we close the year, I hope you’ll consider making a year-end gift to ensure this work accelerates at the scale patients and families need in 2026.
With gratitude,
Audra Moran, President & CEO, OCRA
Year-End Fundraising Update
With just a week remaining, we still need to meet our $2 million year-end fundraising goal, and every dollar counts. Your support strengthens OCRA’s ability to push research forward, expand support programs, and advocate for our community.
Please make your year-end donation today.
New Research Funding
OCRA invested more than $10.8 million toward research initiatives in 2025—part of our $14.5 million commitment this year to strengthen the community through research, patient support, education and advocacy. This year’s grant cycle drew a record number of proposals. We look forward to sharing updates from our newest grantees in 2026.
Collaborating for Cures
OCRA launched the Global Ovarian Cancer Research Consortium, a first-of-its-kind global effort to improve ovarian cancer survival, with partners in Australia, Canada, and the UK, and introduced the upcoming Community Accelerated Research Exchange—a global AI-powered data initiative bringing together patients, advocates, researchers, and clinicians to speed collaboration and accelerate discovery.
Legislative Action
OCRA took important steps in 2025 to strengthen care, access, and support for people impacted by ovarian and gynecologic cancer, while driving meaningful progress at the federal and state levels. From the launch of our new Center for Public Policy and expanded policy priorities to our strongest Advocacy Day yet, this year underscored the power of informed, persistent advocacy. Read a recap in OCRA’s Advocate’s Corner.
Expanded Support and Education
OCRA expanded its support and education programs, doubling Steps 1:1 Counseling in size to serve people with all gynecologic cancers, and introducing new workshops, webinars and roundtables. Engagement grew across our Patient Support Line, Staying Connected Support Series, and Woman to Woman Peer Mentor Program, and our international online conference—free for the first time—drew its highest attendance to date, with participants from more than 60 countries.
Expanded Reach
Two respected organizations joined the OCRA family, strengthening our mission and impact: The Clearity Foundation, known for providing personalized, science-based support, including the Steps 1:1 Counseling Program, and the Rivkin Center for Ovarian Cancer Research, recognized for funding cutting-edge research and initiatives such as the Ovarian Cancer Research Symposium and the SummeRun.
Genetic Testing and Prevention
More than 10,000 people have qualified for free genetic test kits through OCRA’s program, empowering those with risk-elevating genetic mutations to discuss preventive action with their doctors. An analysis of insurance data revealed that nearly half of ovarian cancer patients are not receiving critical genetic testing, as OCRA continued to push for expanded Medicare and Medicaid coverage for genetic testing and treatment, and teamed up with BlackDoctor.org to highlight the importance of genetic testing for Black women, who face disproportionate mortality rates from the disease.
Progress Ahead: Looking to 2026
With your continued support, OCRA will deepen global collaborations, fund scientific discovery, and expand the programs that help patients and families.
Thank you for standing with us as we fight ovarian and gynecologic cancer on every front.
